Real world experience of patients with amyotrophic lateral sclerosis (ALS) in the treatment of spasticity using tetrahydrocannabinol:cannabidiol (THC:CBD)
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Real world experience of patients with amyotrophic lateral sclerosis (ALS) in the treatment of spasticity using tetrahydrocannabinol:cannabidiol (THC:CBD)
Authors
Keywords
Amyotrophic lateral sclerosis, Tetrahydrocannabinol, THC, Cannabidiol, CBD, Spasticity, Patient experience, Treatment satisfaction questionnaire for medication, Net promotor score
Journal
BMC Neurology
Volume 19, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-09-07
DOI
10.1186/s12883-019-1443-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Development and validation of Spasticity Index-Amyotrophic Lateral Sclerosis
- (2018) K. Milinis et al. ACTA NEUROLOGICA SCANDINAVICA
- ‘Oncokompas’, a web-based self-management application to support patient activation and optimal supportive care: a feasibility study among breast cancer survivors
- (2018) Heleen C. Melissant et al. ACTA ONCOLOGICA
- Provision of assistive technology devices among people with ALS in Germany: a platform-case management approach
- (2018) Andreas Funke et al. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial
- (2018) Nilo Riva et al. LANCET NEUROLOGY
- Statistical Models for the Analysis of Zero-Inflated Pain Intensity Numeric Rating Scale Data
- (2017) Joseph L. Goulet et al. JOURNAL OF PAIN
- Amyotrophic lateral sclerosis
- (2017) Michael A van Es et al. LANCET
- Amyotrophic lateral sclerosis
- (2017) Orla Hardiman et al. Nature Reviews Disease Primers
- The musculoskeletal diagnosis cohort
- (2016) Joseph L. Goulet et al. PAIN
- Therapeutic potential of cannabis-related drugs
- (2016) Stephen P.H. Alexander PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
- Identification and outcomes of clinical phenotypes in amyotrophic lateral sclerosis/motor neuron disease: Australian National Motor Neuron Disease observational cohort
- (2016) Paul Talman et al. BMJ Open
- The evidence for symptomatic treatments in amyotrophic lateral sclerosis
- (2014) Thomas M. Jenkins et al. CURRENT OPINION IN NEUROLOGY
- A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis
- (2011) A. Novotna et al. EUROPEAN JOURNAL OF NEUROLOGY
- Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study
- (2011) A. Chio et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols)
- (2011) W Notcutt et al. Multiple Sclerosis Journal
- Tetrahydrocannabinol (THC) for cramps in amyotrophic lateral sclerosis: a randomised, double-blind crossover trial
- (2010) M. Weber et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Validation of an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive medications
- (2009) Murtuza Bharmal et al. Health and Quality of Life Outcomes
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now